THE JOURNAL OF BIOLOGICAL CHEMISTRY
Vol. 271, No. 5, Issue of February 2, pp. 2380 –2382, 1996
© 1996 by The American Society for Biochemistry and Molecular Biology, Inc.
Printed in U.S.A.
Communication
2*,5*-Dideoxyadenosine
3*-Polyphosphates Are Potent
Inhibitors of Adenylyl Cyclases*
(Received for publication, October 16, 1995, and in revised form,
December 8, 1995)
Laurent Désaubry, Ilana Shoshani, and
Roger A. Johnson‡
From the Department of Physiology and Biophysics,
State University of New York, Health Sciences Center,
Stony Brook, New York 11794-8661
Adenylyl cyclase is a family of membrane-bound enzymes
that catalyze the formation of 39:59-cAMP from 59-ATP. In
mammalian systems, the 10 known adenylyl cyclase isozymes
are regulated by numerous hormones and neurotransmitters
via cell surface receptors linked via stimulatory (Gs) and inhibitory (Gi) guanine nucleotide-dependent regulatory proteins
(G-proteins), as well as by numerous other agents also of physiological and biochemical interest. These include agents or enzymes that act on hormone receptors, specific bacterial toxins
that act on Gs and Gi, and agents that act directly on adenylyl
cyclase. Direct activation can be caused by forskolin with all
but one isozyme and by Ca21/calmodulin with four isozymes.
The enzyme is also inhibited directly by certain adenosine
derivatives which act via a distinct domain, referred to as the
“P”-site from a requirement for a purine moiety (1– 8). Of the
mammalian adenylyl cyclases that have been tested, all save
the enzyme from sperm have been found to be susceptible to
P-site-mediated inhibition (5, 9 –12). Although P-site ligands
act directly on adenylyl cyclase, enzyme stimulated by hormones (via Gsa) or Mn21 are most sensitive to inhibition, and
P-site ligands may be viewed as attenuating the enzyme’s
susceptibility to such activation (5, 8, 13–18).
Although the three-dimensional structure of adenylyl cyclase
is not known, the deduced primary sequence suggests a membrane topology exhibiting a repeated structure of six membrane
spanning regions followed by a large cytosolic domain, giving
* This work was supported by National Institutes of Health Research
Grant DK38828 (to R. A. J.) and a Philippe Foundation award (to L. D.).
The costs of publication of this article were defrayed in part by the
payment of page charges. This article must therefore be hereby marked
“advertisement” in accordance with 18 U.S.C. Section 1734 solely to
indicate this fact.
‡ To whom correspondence should be addressed. Tel.: 516-444-3040;
Fax: 516-444-3432; E-mail: rjohnson@ccmail.sunysb.edu.
EXPERIMENTAL PROCEDURES
Preparation and Assay of Adenylyl Cyclase—Detergent-solubilized
preparations of adenylyl cyclase from rat and bovine brains were prepared and assayed as described previously (5, 14, 15). Bovine brain
adenylyl cyclase was purified as described by Pfeuffer et al. (25). Inhibition kinetics were determined on enzyme assayed with concentrations
of divalent cation fixed in excess of the ATP concentration as described
previously (26). Inhibition was determined on enzyme that was activated in the presence of Mn21 and forskolin.
Estimation of Bound Phosphate—Bound phosphate was determined
on ashed samples by the malachite green method of Stull and Buss (23).
Adenine was estimated by uv-absorption at 259 nm following purification on high performance liquid chromatography.
Materials—29,59-dd-39-ADP and 29,59-dd-39-ATP were prepared as
described previously (24). Lubrol PX (from Sigma) was filtered through
alumina (Neutral, AG7, from Bio-Rad Laboratories) to remove peroxides. Recombinant Type I enzyme was generously supplied by Drs. R.
Taussig and A. G. Gilman. Enzyme was purified by forskolin affinity
chromatography from extracts of fall army worm ovarian (Sf9) cells
infected with a Type I adenylyl cyclase encoding baculovirus (27). Other
reagents were of the highest quality from commercial sources.
RESULTS AND DISCUSSION
29,59-Dideoxyadenosine 39-phosphates are a family of inhibitors of adenylyl cyclase in which potency increased with the
number of 39-phosphates (Fig. 1). IC50 values for inhibition of
1
I. Shoshani, R. Taussig, and R. A. Johnson, submitted for
publication.
2
The abbreviations used are: 29,59-dd-39-AMP, 29,59-dideoxyadenosine 39-monophosphate; Ado, adenosine; 29-dAdo, 29-deoxyadenosine;
29,59-dd-39-ADP, 29,59-dideoxyadenosine 39-diphosphate; 29,59-dd-39ATP, 29,59-dideoxyadenosine 39-triphosphate; HPLC, high performance
liquid chromatography; MOPS, 4-morpholinepropanesulfonic acid.
2380
Downloaded from http://www.jbc.org/ by guest on March 2, 2017
2*,5*-Dideoxyadenosine 3*-di- and triphosphates were
tested as inhibitors of brain adenylyl cyclases. With an
IC50 ;40 nM, 2*,5*-dideoxy-3*-ATP is the most potent nonprotein synthetic regulator of adenylyl cyclases thus far
described. Neither 2*,5*-dideoxy-3*-ADP nor 2*,5*dideoxy-3*-ATP inhibited activity by competition with
substrate, and the linear noncompetitive inhibition observed was consistent with interaction via a distinct
domain. The availability of this ligand will permit the
development of a variety of probes that will be extremely useful in investigating adenylyl cyclase structure and the role(s) that this class of compound may play
in physiologically regulating cell function.
twelve membrane spanning regions and two cytosolic domains
(19). The two cytosolic domains (C1 and C2) are homologous
with each other and with the established catalytic domain of
guanylyl cyclases (20), supporting the idea that each contains a
nucleotide binding region. However, it is not known whether
C1, C2, or both form the catalytic site, nor whether one or both
domains participate in inhibition by P-site ligands. Inhibition
kinetics and irreversible inactivation studies with P-site-selective covalent affinity probes are consistent with inhibition occurring at a site that is distinct from the catalytic site (13–15).1
Shared key structural requirements for substrate and for P-site
ligands include a requirement for adenine, enhanced efficacy
with 29-deoxyadenosine derivatives compared with those of
adenosine, and a requirement (catalysis) or preference (inhibition) for phosphate (1–5). Given the shared requirements of
these ligands, some similarities in the binding domains for
each may be expected. Lacking have been high affinity labeled
ligands suitable for binding to either or both domains.
The most potent inhibitory ligands have been 29,59-dideoxyadenosine 39-monophosphate (29,59-dd-39-AMP)2 and the naturally occurring 39-AMP and 29-d-39-AMP, with IC50 values in
the micromolar range (5, 22). In the synthesis of 29,59-dd-39AMP, referred to in a previous study (5), a small amount of a
more potent inhibitory peak also was detected in HPLC eluates. Upon ashing, this unexpected inhibitor was found to
contain two phosphates per adenine (23) and the most likely
product was 29,59-dd-39-ADP. Subsequently, we developed a
synthesis for the 39-polyphosphorylated derivatives of 29,59ddAdo (24). Reported here are the effects of these agents on
adenylyl cyclase and the mode of their inhibition.
2381
Adenylyl Cyclase Inhibition by 29,59-Dideoxy-39-ATP
TABLE I
IC50 values for inhibition of rat brain adenylyl cyclase by adenine
nucleosides and adenine 39-nucleotides
Activities were determined as described for Fig. 1.
Nucleoside
IC50
Adenosine
59-Deoxyadenosine
29-Deoxyadenosine
39-AMP
29-d-39-AMP
29,59-Dideoxyadenosine
29,59-dd-39-AMP
29,59-dd-39-ADP
29,59-dd-39-ATP
82a
17a
15a
8.9a
1.2a
2.7a
0.46
0.10
0.04
mM
a
TABLE II
IC50 values for inhibition of different adenylyl cyclases
by 29,59-dideoxyadenosine 39-polyphosphates
FIG. 1. Inhibition of rat brain adenylyl cyclase by 2*,5*dideoxyadenosine and its 3*-phosphorylated derivatives. Activities were determined in the presence of 5 mM MnCl2, 100 mM 59-ATP, 1
mM 3-isobutyl-1-methylxanthine, 100 mM forskolin, 1 mg of bovine serum albumin per ml, 3 mM dithiothreitol, 0.1% (w/v) Lubrol PX, 50 mM
MOPS buffer, and an ATP-regenerating system including 4 mM phosphoenolpyruvate and 100 mg of pyruvate kinase per ml.
Enzyme source
29,59-dd-39- 29,59-dd-39- 29,59-dd-39AMP
ADP
ATP
nM
Rat brain, detergent extracta
Bovine brain, purifiedb
Type I, purified recombinantd
460
NDc
1990
100
560
250
40
120
170
a
Values from Table I.
Forskolin eluates from forskolin-affinity column as per Ref. 25.
ND, not determined.
d
Forskolin eluate as per Ref. 27.
b
c
FIG. 2. Kinetics of inhibition of purified bovine brain adenylyl
cyclase by 2*,5*-dd-3*-ATP. Activities were determined in the presence of 5 mM MnCl2 in excess of the ATP concentration, 100 mM forskolin, and an ATP-regenerating system including 2 mM creatine phosphate and 100 mg of creatine kinase per ml.
and intercepts were also linear with inhibitor concentration.
This linear noncompetitive behavior was also seen with the
crude, detergent-extracted adenylyl cyclase from rat brain (not
shown) and also with 29,59-dd-39-ADP (not shown). This behavior argues strongly that inhibition occurred at a site distinct
from catalysis and is fully consistent with inhibition occurring
at the P-site. P-site-mediated inhibition of adenylyl cyclases is
characteristically noncompetitive with respect to substrate,
whether MnzATP or MgzATP (1, 3, 7, 8, 13, 14, 16, 28). Thus, the
evidence supports the conclusion that adenylyl cyclases contain
distinct and interacting adenine nucleotide binding domains
for catalysis (59-ATP) and inhibition (29,59-dd-39-ATP).
The straightforward and linear kinetic behavior was somewhat surprising with the cruder detergent extracts as we had
expected that phosphohydrolases might have contributed to
Downloaded from http://www.jbc.org/ by guest on March 2, 2017
the enzyme by these nucleotides are presented in Table I and
are compared with those of the parent nucleoside and with
known ligands. 29,59-dd-39-ADP and 29,59-dd-39-ATP exhibited
IC50 values of 0.1 mM and 0.04 mM, respectively. Potency of the
39-monophosphate (29,59-dd-39-AMP, IC50 ;0.5 mM) was enhanced approximately 5-fold by the addition of the second
phosphate at the 39-position (29,59-dd-39-ADP) and an additional two-plus-fold by the addition of the third phosphate
(29,59-dd-39-ATP). Thus, the most effective inhibitory ligands of
adenylyl cyclase are effected by the removal of both 29- and
59-hydroxyl groups from adenosine and the addition of polyphosphate at the 39-position (Table I). The rank order noted
here was maintained with the purified native bovine type I and
with the recombinant wild type type I adenylyl cyclases, although with these enzymes each of the 39-nucleotides was
noticeably less potent than with the enzyme in the cruder
detergent-dispersed rat brain preparation (Table II). The reason for the loss of inhibitory potency of these 39-nucleotides
upon purification of adenylyl cyclase is unknown but is consistent with previously noted observations with 29-d-39-AMP and
29,59-ddAdo with the bovine brain enzyme (5). The reduced
sensitivity may be due simply to the changes in structure of the
enzyme upon isolation and removal of the native phospholipid
environment.
29,59-dd-39-ATP (IC50 ;40 nM) is almost two orders of magnitude more potent than previous ligands in inhibiting native
adenylyl cyclase. It the most potent non-protein regulator of
adenylyl cyclases thus far described. Since inhibition was also
observed with purified adenylyl cyclase, it is clear that 29,59dd-39-ATP acts directly on the enzyme, exerting inhibition independent of either hormone receptor, stimulatory or inhibitory G-protein, or G-protein subunit. It approaches the potency
of the stimulatory effect of rGsa on the type I adenylyl cyclase
and the stimulatory and inhibitory effects of bg on as-activated
types II and I, respectively (27).
Structurally, 29,59-dd-39-ATP and 29,59-dd-39-ADP share
some properties with 59-ATP. To ascertain whether either 39nucleotide might inhibit activity through simple competition
with 59-ATP at the catalytic site, inhibition kinetics were evaluated (Fig. 2). In this experiment, inhibition by 29,59-dd-39-ATP
of the forskolin affinity-purified enzyme from bovine brain was
found to be noncompetitive with respect to substrate. Moreover, inhibiton was linear (Fig. 2, inset) in that replots of slopes
Values from Ref. 5.
2382
Adenylyl Cyclase Inhibition by 29,59-Dideoxy-39-ATP
significant breakdown of the 39-polyphosphates (21). However,
we noted no meaningful breakdown of either nucleotide during
assay incubations either with purified or with the crude Lubrol
PX-extracted adenylyl cyclase.
The inhibitory potency of 29,59-dd-39-ATP suggests that derivatives of it may be useful as a labeled ligand to probe the
P-site binding domain on adenylyl cyclase. This could circumvent one of the major constraints in the identification of amino
acids involved in the binding of P-site ligands. Presently one
must rely on inhibition of catalysis, even for evaluating efficacy
of site-directed mutations of expressed protein. With inhibition
as end point one is by definition not directly quantifying a
single domain on this enzyme, but is rather measuring a downstream event. Changes in catalysis could occur independent of
changes in the binding of inhibitory ligand, simply through
modification of a domain that influences coupling between inhibitory and catalytic domains. The affinity of 29,59-dd-39-ATP
is sufficient to allow a binding assay to be developed, and this
could significantly aid studies in this direction.
REFERENCES
1. Weinryb, I., and Michel, I. M. (1974) Biochim. Biophys. Acta 334, 218 –225
2. Londos, C., and Wolff, J. (1977) Proc. Natl. Acad. Sci. U. S. A. 74, 5482–5486
3. Haslam, R. J., Davidson, M. M. L., and Desjardins, J. V. (1978) Biochem. J.
176, 83–95
4. Wolff, J., Londos, C., and Cooper, D. M. F. (1981) Adv. Cyclic Nucleotide Res.
Downloaded from http://www.jbc.org/ by guest on March 2, 2017
Acknowledgments—We are grateful to Drs. R. Taussig and A. G.
Gilman for providing the recombinant type I adenylyl cyclase used in
some of the experiments referred to here.
14, 199 –214
5. Johnson, R. A., Yeung, S.-M. H., Stübner, D., Bushfield, M., and Shoshani, I.
(1989) Mol. Pharmacol. 35, 681– 688
6. Fain, J. N., Pointer, R. H., and Ward, W. F. (1972) J. Biol. Chem. 247,
6866 – 6872
7. Haslam, R. J., and Lynham, J. A. (1972) Life Sci. 11, 1143–1154
8. McKenzie, S. G., and Baer, H. P. (1973) Canad. J. Physiol. Pharmacol. 51,
190 –196
9. Johnson, R. A., and Shoshani, I. (1990) J. Biol. Chem. 265, 19035–19039
10. Tang, W.-J., Krupinski, J., and Gilman, A. G. (1991) J. Biol. Chem. 266,
8595– 8603
11. Premont, R., Chen, J., Ma, H. W., Ponnapalli, M., and Iyengar, R. (1992)
Proc. Natl. Acad. Sci. U. S. A. 89, 9809 –9813
12. Lyons, E., Jr., Shoshani, I., Iyengar, R., and Johnson, R. A. (1994) Fed. Proc.
8, A1418
13. Johnson, R. A., Saur, W., and Jakobs, K. H. (1979) J. Biol. Chem. 254,
1094 –1101
14. Johnson, R. A., and Shoshani, I. (1990) J. Biol. Chem. 265, 11595–11600
15. Yeung, S. M. H., and Johnson, R. A. (1990) J. Biol. Chem. 265, 16745–16750
16. Londos, C., and Preston, M. S. (1977) J. Biol. Chem. 252, 5951–5956
17. Florio, V. A., and Ross, E. M. (1983) Mol. Pharmacol. 24, 195–202
18. Stübner, D., and Johnson, R. A. (1989) FEBS Lett. 248, 155–161
19. Krupinski, J., Coussen F., Bakalyar, H. A., Tang, W.-J., Feinstein, P. G., Orth,
K., Slaughter, C., Reed, R. R., and Gilman, A. G. (1989) Science 244,
1558 –1564
20. Koesling, D., Böhme, E., and Schultz, G. (1991) FASEB J. 5, 2785–2791
21. Johnson, R. A. (1980) J. Biol. Chem. 255, 8252– 8258
22. Bushfield, M., Shoshani, I., and Johnson, R. A. (1990) Mol. Pharmacol. 38,
848 – 853
23. Stull, J. T., and Buss, J. E. (1977) J. Biol. Chem. 252, 851– 857
24. Désaubry, L., Shoshani, I., and Johnson, R. A. (1995) Tetrahedron Lett. 36,
995–996
25. Pfeuffer, E., Mollner, S., and Pfeuffer, T. (1985) EMBO J. 4, 3675–3679
26. Garbers, D. L., and Johnson, R. A. (1975) J. Biol. Chem. 250, 8449 – 8456
27. Taussig, R., Quarmby, L. M., and Gilman, A. G. (1993) J. Biol. Chem. 268,
9 –12
28. Johnson, R. A., and Welden, J. (1977) Arch. Biochem. Biophys. 183, 216 –227
2′,5′-Dideoxyadenosine 3′-Polyphosphates Are Potent Inhibitors of Adenylyl Cyclases
Laurent Désaubry, Ilana Shoshani and Roger A. Johnson
J. Biol. Chem. 1996, 271:2380-2382.
doi: 10.1074/jbc.271.5.2380
Access the most updated version of this article at http://www.jbc.org/content/271/5/2380
Alerts:
• When this article is cited
• When a correction for this article is posted
Click here to choose from all of JBC's e-mail alerts
Downloaded from http://www.jbc.org/ by guest on March 2, 2017
This article cites 28 references, 19 of which can be accessed free at
http://www.jbc.org/content/271/5/2380.full.html#ref-list-1